Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2006, Article ID 26875, 7 pages
http://dx.doi.org/10.1155/MI/2006/26875
Research Communication

Interleukin-10 in the Pathophysiology of Inflammatory Bowel Disease: Increased Serum Concentrations During the Recovery Phase

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Asahi-machi 67, Kurume 830-0011, Japan

Received 19 June 2006; Revised 10 August 2006; Accepted 10 August 2006

Copyright © 2006 Keiichi Mitsuyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D K Podolsky and C Fiocchi, “Cytokines, chemokines, growth factors, eicosanoids, and other bioactive molecules in inflammatory bowel disease,” in Inflammatory Bowel Disease, J B Kirsner, Ed., pp. 191–207, W.B.Saunders, Philadelphia, Pa, 5th edition, 2000. View at Google Scholar
  2. F Cominelli, K O Arseneau, and T T Pizarro, “The mucosal inflammatory response. Cytokines and chemokines,” in Inflammatory Bowel Disease: From Bench to Bedside, S R Targan, F Shanahan, and L C Karp, Eds., pp. 147–176, Kluwer Academic, Dordrecht, The Netherland, 2nd edition, 2003. View at Google Scholar
  3. F Shanahan and S R Targan, “Mechanisms of tissue injury in inflammatory bowel disease,” in Inflammatory Bowel Disease: From Bench to Bedside, S R Targan and F Shanahan, Eds., pp. 78–88, Williams & Wilkins, Baltimore, Md, 1994. View at Google Scholar
  4. J A Katz, J Itoh, and C Fiocchi, “Pathogenesis of inflammatory bowel disease,” Current Opinion in Gastroenterology, vol. 15, no. 4, pp. 291–297, 1999. View at Publisher · View at Google Scholar
  5. D K Podolsky, “Inflammatory bowel disease (first of two parts),” New England Journal of Medicine, vol. 325, no. 13, pp. 928–937, 1991. View at Google Scholar
  6. K L Isaacs, R B Sartor, and S Haskill, “Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification,” Gastroenterology, vol. 103, no. 5, pp. 1587–1595, 1992. View at Google Scholar
  7. D F Fiorentino, M W Bond, and T R Mosmann, “Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones,” Journal of Experimental Medicine, vol. 170, no. 6, pp. 2081–2095, 1989. View at Publisher · View at Google Scholar
  8. M Howard and A O'Garra, “Biological properties of interleukin 10,” Immunology Today, vol. 13, no. 6, pp. 198–200, 1992. View at Publisher · View at Google Scholar
  9. D F Fiorentino, A Zlotnik, T R Mosmann, M Howard, and A O'Garra, “IL-10 inhibits cytokine production by activated macrophages,” Journal of Immunology, vol. 147, no. 11, pp. 3815–3822, 1991. View at Google Scholar
  10. R de Waal Malefyt, J Abrams, B Bennett, C G Figdor, and J E de Vries, “Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes,” Journal of Experimental Medicine, vol. 174, no. 5, pp. 1209–1220, 1991. View at Publisher · View at Google Scholar
  11. C Bogdan, J Paik, Y Vodovotz, and C Nathan, “Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10,” Journal of Biological Chemistry, vol. 267, no. 32, pp. 23301–23308, 1992. View at Google Scholar
  12. J Andersson, S Nagy, L Bjork, J Abrams, S Holm, and U Andersson, “Bacterial toxin-induced cytokine production studied at the single-cell level,” Immunological Reviews, no. 127, pp. 69–96, 1992. View at Publisher · View at Google Scholar
  13. R Kuhn, J Lohler, D Rennick, K Rajewsky, and W Muller, “Interleukin-10-deficient mice develop chronic enterocolitis,” Cell, vol. 75, no. 2, pp. 263–274, 1993. View at Publisher · View at Google Scholar
  14. S Schreiber, T Heinig, H-G Thiele, and A Raedler, “Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease,” Gastroenterology, vol. 108, no. 5, pp. 1434–1444, 1995. View at Publisher · View at Google Scholar
  15. S C Truelove and L J Witts, “Cortisone in ulcerative colitis: final report on a therapeutic trial,” British Medical Journal, vol. 2, no. 4947, pp. 1041–1048, 1955. View at Google Scholar
  16. J Myren, I AD Bouchier, G Watkinson, A Softley, S E Clamp, and F T de Dombal, “The OMGE multinational inflammatory bowel disease survey 1976–1982. A further report on 2657 cases,” Scandinavian Journal of Gastroenterology, vol. 19, no. suppl 95, pp. 1–27, 1984. View at Google Scholar
  17. F T de Dombal and A Softley, “IOIBD report no. 1: observer variation in calculating indices of severity and activity in Crohn's disease,” Gut, vol. 28, no. 4, pp. 474–481, 1987. View at Google Scholar
  18. M Honda, S Yamamoto, M Cheng et al., “Human soluble IL-6 receptor: its detection and enhanced release by HIV infection,” Journal of Immunology, vol. 148, no. 7, pp. 2175–2180, 1992. View at Google Scholar
  19. W H Gotlieb, J S Abrams, J M Watson, T J Velu, J S Berek, and O Martínez-Maza, “Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers,” Cytokine, vol. 4, no. 5, pp. 385–390, 1992. View at Publisher · View at Google Scholar
  20. K Mitsuyama, M Sata, and K Tanikawa, “Significance of interleukin-6 in patients with inflammatory bowel disease,” Gastroenterologia Japonica, vol. 26, no. 1, pp. 20–28, 1991. View at Google Scholar
  21. K Mitsuyama, E Sasaki, A Toyonaga et al., “Colonic mucosal interleukin-6 in inflammatory bowel disease,” Digestion, vol. 50, no. 2, pp. 104–111, 1991. View at Google Scholar
  22. K Mitsuyama, A Toyonaga, E Sasaki et al., “Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6,” Gut, vol. 36, no. 1, pp. 45–49, 1995. View at Google Scholar
  23. T Kucharzik, R Stoll, N Lugering, and W Domschke, “Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD),” Clinical and Experimental Immunology, vol. 100, no. 3, pp. 452–456, 1995. View at Google Scholar
  24. O H Nielsen, T Køppen, N Rüdiger, T Horn, J Eriksen, and I Kirman, “Involvement of interleukin-4 and -10 in inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 41, no. 9, pp. 1786–1793, 1996. View at Publisher · View at Google Scholar
  25. Y R Mahida, L Kurlac, A Gallagher, and C J Hawkey, “High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis,” Gut, vol. 32, no. 12, pp. 1531–1534, 1991. View at Google Scholar
  26. K Mitsuyama, N Tomiyasu, A Suzuki et al., “A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease,” Clinical and Experimental Immunology, vol. 143, no. 1, pp. 125–131, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. X Zhou, P Schmidtke, F Zepp, and C U Meyer, “Boosting interleukin-10 production: therapeutic effects and mechanisms,” Current Drug Targets: Immune, Endocrine & Metabolic Disorders, vol. 5, no. 4, pp. 465–475, 2005. View at Google Scholar
  28. T Nishiyama, K Mitsuyama, A Toyonaga, E Sasaki, and K Tanikawa, “Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease,” Digestion, vol. 55, no. 6, pp. 368–373, 1994. View at Google Scholar
  29. V Casini-Raggi, L Kam, Y JT Chong, C Fiocchi, T T Pizarro, and F Cominelli, “Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation,” Journal of Immunology, vol. 154, no. 5, pp. 2434–2440, 1995. View at Google Scholar
  30. C A Dinarello and R C Thompson, “Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro,” Immunology Today, vol. 12, no. 11, pp. 404–410, 1991. View at Publisher · View at Google Scholar
  31. S JH van Deventer, C O Elson, and R N Fedorak, “Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's disease study group,” Gastroenterology, vol. 113, no. 2, pp. 383–389, 1997. View at Publisher · View at Google Scholar
  32. R N Fedorak, A Gangl, C O Elson et al., “Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group,” Gastroenterology, vol. 119, no. 6, pp. 1473–1482, 2000. View at Publisher · View at Google Scholar
  33. S Schreiber, R N Fedorak, O H Nielsen et al., “Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group,” Gastroenterology, vol. 119, no. 6, pp. 1461–1472, 2000. View at Publisher · View at Google Scholar
  34. M-C Li and S-H He, “IL-10 and its related cytokines for treatment of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 10, no. 5, pp. 620–625, 2004. View at Google Scholar
  35. A Zdanov, “Structural features of the interleukin-10 family of cytokines,” Current Pharmaceutical Design, vol. 10, no. 31, pp. 3873–3884, 2004. View at Publisher · View at Google Scholar